Products for Research Use Only

MIP-1095 (TFA)

CAT: 0804-HY-123733A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123733A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled (131I labeled) as an imaging probe to indicate tumor progression. And 131I-MIP-1095 showed higher renal uptake in mice[1][2].
Product Name Alternative
RPS-001 (TFA)
UNSPSC
12352005
Target
PSMA
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mip-1095-tfa.html
Purity
99.76
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C([C@H](CCC(O)=O)NC(N[C@@H](CCCCNC(NC1=CC=C(C=C1)I)=O)C(O)=O)=O)O.OC(C(F)(F)F)=O
Molecular Formula
C21H26F3IN4O10
Molecular Weight
678.35
References & Citations
[1]Zechmann CM, et al. Radiation dosimetry and first therapy results with a (124) I/ (131) I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41 (7) :1280-92.|[2]Kelly JM, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58 (9) :1442-1449.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported